COMMUNIQUÉS West-GlobeNewswire

Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a calcium release-activated calcium (CRAC) channel inhibitor and RP10107, a glutaminase inhibitor at the 2018 AACR Annual Meeting
10/04/2018
La Chaux-de-Fonds, Switzerland, April 10, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class CRAC channel inhibitor and RP10107, a novel and [...]
ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology
10/04/2018
Key Updates Dr. Peter A. Beal joins ProQR’s scientific advisory board, bringing with him tremendous experience in the field of RNA-based therapeutics, particularly in the area of RNA editing. As an expert in the field [...]
Cara Therapeutics Announces Participation in 2018 Spring Clinical Meetings of the National Kidney Foundation
10/04/2018
STAMFORD, Conn., April 10, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA ), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and [...]
Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 Clinical Programs
10/04/2018
Successful broad signal-seeking efforts identify T-cell lymphoma as an indication responsive to TTI-621 therapy. Focusing TTI-621 intravenous trial on separate cutaneous and peripheral T-cell lymphoma cohorts employing [...]
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Previously Treated Hepatocellular Carcinoma
10/04/2018
CAMBRIDGE, Mass. and BEIJING, China, April 10, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly [...]
CellAegis Announces First Patients Enrolled in U.S. SHIELD Pivotal Clinical Trial
10/04/2018
TORONTO, April 10, 2018 (GLOBE NEWSWIRE) -- CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for [...]
Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies (DEE)
10/04/2018
DEVON, Pa., April 10, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE ), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative [...]
Neuralstem Announces First Surgery Completed in Cervical Cohort of Phase 1 Clinical Trial in Patients with Chronic Spinal Cord Injury
10/04/2018
GERMANTOWN, Md., April 10, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq: CUR ), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, today [...]
Loxo Oncology and Illumina to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics
10/04/2018
- Expands Illumina’s Oncology Offerings for NextSeq™ 550Dx with a Companion Diagnostic Version of TruSight™ Tumor 170 for Solid Tumors - - Loxo Oncology to Utilize a Companion Diagnostic Version of TruSight Tumor 170 [...]
HealthLynked Corp. Announces Release of New Network Service Allowing Creation and Management of Profiles for Children
10/04/2018
NAPLES, Fla., April 10, 2018 (GLOBE NEWSWIRE) -- HealthLynked Corp. (OTCQB:HLYK) today announced release of its latest software updates to the HealthLynked Network. The new features allow parents to create profiles for [...]
PotNetwork Holdings, Inc. Sets New Monthly Sales Record in March 2018, With $2.2 Million in Sales
10/04/2018
Innovative CBD Industry Pioneer Records 152% Increase in Year-Over-Year Revenues FT LAUDERDALE, Fla., April 10, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE--PotNetwork Holding, Inc. (OTC Pink:POTN) On Tuesday, April 10, [...]
Publishing of Orion Corporation's Interim Report for January-March 2018 on 24 April 2018
10/04/2018
ORION CORPORATION PRESS RELEASE 10 APRIL 2018 at 12.00 EEST Publishing of Orion Corporation's Interim Report for January-March 2018 on 24 April 2018 Orion will publish its Interim Report for January-March 2018 on [...]
Shire plc : Rule 2.9 Announcement
10/04/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 10 April 2018 [...]
Summit Therapeutics plc : Director/PDMR Shareholding
10/04/2018
Summit Therapeutics plc ("Summit" or the "Company") Non-Executive Director Share Option Update Oxford, UK, 10 April 2018 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company [...]
Motif Bio Reports Fiscal Year 2017 Results
10/04/2018
NEW YORK, April 10, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ: MTFB ), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial results for the [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
10/04/2018
REGULATED INFORMATION GHENT, Belgium, 10 April 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
10/04/2018
REGULATED INFORMATION GHENT, Belgium, 10 April 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
Biocartis Group NV: Invitation to Annual Shareholders' Meeting
10/04/2018
PRESS RELEASE : REGULATED INFORMATION10 April 2018, 07:00 CEST Invitation to Annual Shareholders' Meeting Biocartis to propose new board composition Mechelen, Belgium, 10 April 2018 - Biocartis Group NV (the 'Company' [...]
Epizyme Announces Publication of Tazemetostat Phase 1 Clinical Data in The Lancet Oncology
10/04/2018
Study Evaluated the Safety of Tazemetostat and Established the Recommended Phase 2 Dose; Anti-Tumor Activity Observed in Multiple Tumor Types CAMBRIDGE, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ: [...]

Pages